Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | HRAS |
Variant | Q61K |
Impact List | missense |
Protein Effect | loss of function |
Gene Variant Descriptions | HRAS Q61K does not lie within any known functional domains of the Hras protein (UniProt.org). Q61K results in decreased Hras GTPase activity and leads to transformation of cells in culture (PMID: 3510078). |
Associated Drug Resistance | |
Category Variants Paths |
HRAS mutant HRAS act mut HRAS Q61K HRAS mutant HRAS Q61X HRAS Q61K |
Transcript | NM_005343.4 |
gDNA | chr11:g.533875G>T |
cDNA | c.181C>A |
Protein | p.Q61K |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_005343.3 | chr11:g.533875G>T | c.181C>A | p.Q61K | RefSeq | GRCh38/hg38 |
NM_176795.5 | chr11:g.533875G>T | c.181C>A | p.Q61K | RefSeq | GRCh38/hg38 |
NM_001130442.3 | chr11:g.533875G>T | c.181C>A | p.Q61K | RefSeq | GRCh38/hg38 |
NM_005343.4 | chr11:g.533875G>T | c.181C>A | p.Q61K | RefSeq | GRCh38/hg38 |
NM_176795 | chr11:g.533875G>T | c.181C>A | p.Q61K | RefSeq | GRCh38/hg38 |
NM_176795.4 | chr11:g.533875G>T | c.181C>A | p.Q61K | RefSeq | GRCh38/hg38 |
NM_005343 | chr11:g.533875G>T | c.181C>A | p.Q61K | RefSeq | GRCh38/hg38 |
NM_001130442 | chr11:g.533875G>T | c.181C>A | p.Q61K | RefSeq | GRCh38/hg38 |
NM_001130442.2 | chr11:g.533875G>T | c.181C>A | p.Q61K | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF G466E HRAS Q61K | melanoma | sensitive | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of a melanoma cell line harboring BRAF G466E and HRAS Q61K in culture (PMID: 28783719). | 28783719 |
HRAS Q61K PTEN dec exp | rhabdomyosarcoma | resistant | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, decreasing Pten expression through shRNA knockdown in a rhabdomyosarcoma cell line harboring HRAS Q61K conferred resistance to Mekinist (trametinib) treatment in culture (PMID: 36322002). | 36322002 |
HRAS Q61K PTEN dec exp | rhabdomyosarcoma | sensitive | Ganitumab + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Ganitumab (AMG-479) sensitized a rhabdomyosarcoma cell line harboring HRAS Q61K with low PTEN expression to treatment with Mekinist (trametinib), resulting in reduced cell growth in culture (PMID: 36322002). | 36322002 |